xen901
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 19, 2018 (NCT03467100)
Timeline
Indications
Mechanism of action
SCN8A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05493293 | Phase 2 | Nov 9, 2022 | Neurocrine Biosciences |
| NCT05226780 | Phase 2 | Jul 12, 2022 | Neurocrine Biosciences |
| NCT05159908 | Phase 2 | Jan 31, 2022 | Neurocrine Biosciences |
| NCT04873869 | Phase 2 | Dec 31, 2021 | Neurocrine Biosciences |
| NCT03467100 | Phase 1 | Feb 19, 2018 | Xenon Pharmaceuticals Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Neurocrine Biosciences | For profit | 4 | 4 | 1 | 2021 |
| Xenon Pharmaceuticals Inc. | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1